Leukotriene inhibitors in sinusitis

Current Infectious Disease Reports

Volumn 14, Issue 2, 2012, Pages 147-154

  Steinke, John W ^a,b   Kennedy, Joshua L ^a,b  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Arachidonic acid; Inhibitor; Leukotriene; Receptor; Sinusitis

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONIC ACID; CYSTEINE; CYTOKINE; G PROTEIN COUPLED RECEPTOR; LEUKOTRIENE; LEUKOTRIENE B4; LEUKOTRIENE RECEPTOR; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MEMBRANE PHOSPHOLIPID; MEPOLIZUMAB; MONTELUKAST; NEUROKININ A; PHOSPHOLIPASE; PHOSPHOLIPASE A2; PRANLUKAST; SUBSTANCE P; ZAFIRLUKAST; ZILEUTON;

ARTICLE; CELL TYPE; CHRONIC SINUSITIS; CHURG STRAUSS SYNDROME; DRUG MECHANISM; DRUG STRUCTURE; EOSINOPHIL; HUMAN; RECEPTOR BINDING; SINUSITIS; SUSTAINED RELEASE FORMULATION;

EID: 84862854973     PISSN: 15233847     EISSN: 15343146     Source Type: Journal    
DOI: 10.1007/s11908-012-0245-9     Document Type: Article

References (74)

1. Benninger MS, Ferguson BJ, Hadley JA, et al. Adult chronic rhinosinusitis: definitions, diagnosis, epidemiology, and pathophysiology. Otolaryngol Head Neck Surg. 2003;129:S1-S32.
2. Meltzer EO, Hamilos DL, Hadley JA, et al. Rhinosinusitis: establishing definitions for clincal research and patient care. J Allergy Clin Immunol. 2004;114:S155-212.
3. Slavin RG, Spector SL, Berstein IL, et al. The diagnosis and management of sinusitis: a practice parameter update. J Allergy Clin Immunol. 2005;116:S13-47. (Pubitemid 41715240)
4. Payne SC, Borish L, Steinke JW. Genetics and phenotyping in chronic sinusitis. J Allergy Clin Immunol. 2011;in press. Rather than lumping all forms of sinusitis together, this paper discusses the various subtypes of sinusitis and different approaches to treatment.
5. Yopp AC, Randolph GJ, Bromberg JS. Leukotrienes, sphingolipids, and leukocyte trafficking. J Immuol. 2003;171:5-10. (Pubitemid 36745265)
6. Peters-Golden M, Brock TG. Intracellular compartmentalization of leukotriene synthesis: unexpected nuclear secrets. FEBS Lett. 2001;487:323-6. (Pubitemid 32121750)
7. Ferguson AD, McKeever BM, Xu S, et al. Crystal structure of inhibitor-bound human 5-lipoxygenase-activating protein. Science. 2007;317:510-2. (Pubitemid 47196114)
8. Ago H, Kanaoka Y, Irikura D, et al. Crystal structure of a human membrane protein involved in cysteinyl leukotriene biosynthesis. Nature. 2007;448:609-12. (Pubitemid 47206929)
9. Christmas P, Weber BM, McKee M, et al. Membrane localization and topology of leukotriene C4 synthase. J Biol Chem. 2002;277:28902-8.
10. Lynch KR, O'Neill GP, Liu Q, et al. Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature. 1999;399:789-93. (Pubitemid 29293175)
11. Heise CE, O'Dowd BF, Figueroa DJ, et al. Characterization of the human cysteinyl leukotriene 2 receptor. J Biol Chem. 2000;275:30531-6.
12. Walch L, Norel X, Back M, et al. Pharmacological evidence for a novel cysteinyl-leukotriene receptor subtype in human pulmonary artery smooth muscle. Br J Pharmacol. 2002;137:1339-45. (Pubitemid 36071752)
13. Nonaka Y, Hiramoto T, Fujita N. Identification of endogenous surrogate ligands for human P2Y12 receptors by in silico and in vitro methods. Biochem Biophys Res Commun. 2005;337:281-8. (Pubitemid 41393791)
14. Paruchuri S, Tashimo H, Feng C, et al. Leukotriene E4-induced pulmonary inflammation is mediated by the P2Y12 receptor. J Exp Med. 2009;206:2543-2555. This is one of the first papers that describes a receptor for LTE4, providing functional evidence in support of previous pharmacological data.
15. Maekawa A, Kanaoka Y, Xing W, et al. Functional recognition of a distinct receptor preferential for leukotriene E4 in mice lacking the cysteinyl leukotriene 1 and 2 receptors. Proc Natl Acad Sci U S A. 2008;105:16695-16700. Using knock-out mice this papers demonstrates that a receptor for LTE4 exists based on responsiveness to LTE4 in the absence of other known CysLT receptors.
16. Ciana P, Fumagalli M, Trincavelli ML, et al. The orphan receptor GPR17 identified as a new dual uracil nucleotides/cysteinyl-leukotrienes receptor. EMBO J. 2006;25:4615-27. (Pubitemid 44498134)
17. Maekawa A, Balestrieri B, Austen KF, et al. GPR17 is a negative regulator of the cysteinyl leukotriene 1 receptor response to leukotriene D4. Proc Natl Acad Sci U S A. 2009;106:11685-90.
18. Wunder F, Tinel H, Kast R, et al. Pharmacological characterization of the first potent and selective antagonist at the cysteinyl leukotriene 2 (CysLT(2)) receptor. Br J Pharmacol. 160:399-409.
19. Figueroa DJ, Breyer R, Defoe S, et al. Expression of the cysteinyl leukotriene 1 receptor in normal human lung and peripheral blood leukocytes. Am J Crit Care Med. 2001;163:226-33. (Pubitemid 32095274)
20. Figueroa DJ, Borish L, Baramki D, et al. Expression of cysteinyl leukotriene synthetic and signaling proteins in inflammatory cells in active seasonal allergic rhinitis. Clin Exp Allergy. 2003;33:1380-8. (Pubitemid 37289934)
21. Sousa AR, Parikh A, Scadding G, et al. Leukotriene-receptor expression on nasal mucosal inflammatory cells in asprinsensitive rhinosinusitis. N Engl J Med. 2002;347:1493-9. (Pubitemid 35257588)
22. Sjostrom M, Johansson AS, Schroder O, et al. Dominant expression of the CysLT2 receptor accounts for calcium signaling by cysteinyl leukotrienes in human umbilical vein endotheilial cells. Arterioscler Thromb Vasc Biol. 2003;23:E37-41.
23. Yoshisue H, Kirkham-Brown J, Healy E, et al. Cysteinyl leukotrienes synergize with growth factors too induce proliferation of human bronchial fibroblasts. J Allergy Clin Immunol. 2007;119:132-40. (Pubitemid 46037796)
24. Steinke JW, Crouse CD, Bradley D, et al. Characterization of interleukin-4 stimulated nasal polyp fibroblasts. Am J Respir Cell Mol Biol. 2004;30:212-9. (Pubitemid 38147206)
25. Tager AM, Luster AD. BLT1 and BLT2: the leukotriene B(4) receptors. Prost Leukot Essent Fatty Acids. 2003;69:123-34.
26. Yokomizo T, Izumi T, Shimizu T. Co-expression of two LTB4 receptors in human mononuclear cells. Life Sci. 2001;68:2207-12. (Pubitemid 32452375)
27. Mellor EA, Austen KF, Boyce JA. Cysteinyl leukotrienes and uridine diphosphate induce cytokine generation by human mast cells through an interleukin 4-regulated pathway that is inhibited by leukotriene receptor antagonists. J Exp Med. 2002;195:583-92. (Pubitemid 34461503)
28. Mellor EA, Frank N, Soler D, et al. Expression of the type 2 receptor for cysteinyl leukotrienes (CysLT2R) by human mast cells: Functional distinction from CysLT1R. Proc Natl Acad Sci U S A. 2003;100:11589-93. (Pubitemid 37205980)
29. Thivierge M, Stankova J, Rola-Pleszczynski M. IL-13 and IL-4 up-regulate cysteinyl leukotriene 1 receptor expression in human monocytes and macrophages. J Immunol. 2001;167:2855-60. (Pubitemid 32768919)
30. Early SB, Barekzi E, Negri J, et al. Concordant modulation of cysteinyl leukotriene receptor expression by IL-4 and IFN-γ on peripheral immune cells. Am J Respir Cell Mol Biol. 2007;36:715-20. (Pubitemid 46871426)
31. Fujii M, Tanaka H, Abe S. Interferon-gamma up-regulates expression of cysteinyl leukotriene type 2 receptors on eosinophils in asthmatic patients. Chest. 2005;128:3148-55. (Pubitemid 41698634)
32. Lotzer K, Spanbroek R, Hildner M, et al. Differential leukotriene receptor expression and calcium responses in endothelial cells and macrophages indicate 5-lipoxygenase-dependent circuits of inflammation and atherogenesis. Arterioscler Thromb Vasc Biol. 2003;23:e32-6.
33. Woszczek G, Chen LY, Nagineni S, et al. IFN-gamma induces cysteinyl leukotriene receptor 2 expression and enhances the responsiveness of human endothelial cells to cysteinyl leukotrienes. J Immunol. 2007;178:5262-70. (Pubitemid 46595311)
34. Thivierge M, Doty M, Johnson J, et al. IL-5 up-regulates cysteinyl leukotriene 1 receptor expression in HL-60 cells differentiated into eosinophils. J Immunol. 2000;165:5221-6.
35. Qiu H, Johansson AS, Sjostrom M, et al. Differential induction of BLT receptor expression on human endothelial cells by lipopolysaccharide, cytokines, and leukotriene B4. Proc Natl Acad Sci U S A. 2006;103:6913-8.
36. Samter M, Beers Jr RF. Intolerance to aspirin. Clinical studies and consideration of its pathogenesis. Ann Intern Med. 1968;68:975-83.
37. Szczeklik A, Nizankowska E. Clinical features and diagnosis of aspirin induced asthma. Thorax. 2000;55:S42-6.
38. Steinke JW, Bradley D, Arango P, et al. Cytseinyl leukotriene expression in chronic hyperplastic sinusitis-nasal polyposis: importance to eosinophilia and asthma. J Allergy Clin Immunol. 2003;111:342-9. (Pubitemid 36228556)
39. Perez-Novo CA, Watelet JB, Claeys C, et al. Prostaglandin, leukotiene, and lipoxin balance in chronic rhinosinusitis with and without nasal polyposis. J Allergy Clin Immunol. 2005;115:1189-96. (Pubitemid 40824588)
40. Cowburn AS, Sladek K, Soja J, et al. Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirinintolerant asthma. J Clin Invest. 1998;101:834-46. (Pubitemid 28096081)
41. Adamjee J, Suh YJ, Park HS, et al. Expression of 5-lipoxygenase and cyclooxygenase pathway enzymes in nasal polyps of patients with aspirin-intolerant asthma. J Pathol. 2006;209:392-9. (Pubitemid 43997749)
42. Christie PE, Tagari P, Ford-HutchinsonAW, et al. Urinary leukotriene E4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects. Am Rev Respir Dis. 1991;143:1025-9.
43. Corrigan C, Mallett K, Ying S, et al. Expression of the cysteinyl leukotriene receptors cysLT(1) and cysLT(2) in aspirin-sensitive and aspirin-tolerant chronic rhinosinusitis. J Allergy Clin Immunol. 2005;115:316-22. (Pubitemid 40215095)
44. Bachert C, Wagenmann M, Hauser U, et al. IL-5 synthesis is upregulated in human nasal polyp tissue. J Allergy Clin Immunol. 1997;99:837-42. (Pubitemid 27280376)
45. Bachert C, Gevaert P, van Cauwenberge P. Nasal polyposis-a new concept on the formation of polyps. ACI International. 1999;11:130-5. (Pubitemid 29347016)
46. Elovic A, Wong DT, Weller PF, et al. Expression of transforming growth factors-alpha and beta 1 messenger RNA and product by eosinophils in nasal polyps. J Allergy Clin Immunol. 1994;93:864-9. (Pubitemid 24154104)
47. Van Zele T, Claeys S, Gevaert P, et al. Differentiation of chronic sinus diseases by measurement of inflammatory mediators. Allergy. 2006;61:1280-9. (Pubitemid 44465587)
48. Minshall EM, Cameron L, Lavigne F, et al. Eotaxin mRNA and protein expression in chronic sinusitis and allergen-induced nasal responses in seasonal allergic rhinitis. Amer J Resp Cell Mol Biol. 1997;17:683-90. (Pubitemid 127348659)
49. Hamilos DL, Leung DYM, Huston DP, et al. GM-CSF, IL-5, and RANTES immunoreactivity and mRNA expression in chronic hyperplastic sinusitis with nasal polyposis. Clin Exp Allergy. 1998;28:1145-52. (Pubitemid 28432638)
50. Israel E, Fischer AR, Rosenberg MA, et al. The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. Amer Rev Respir Dis. 1993;148:1447-51. (Pubitemid 24002469)
51. Sladek K, Szczeklik A. Cysteinyl leukotrienes overproduction and mast cell activation in aspirn-provoked bronchospasm in asthma. Eur Respir J. 1993;6:391-9. (Pubitemid 23114887)
52. Daffern PJ, Muilenburg D, Hugli TE, et al. Association of urinary leukotriene E4 excretion during aspirin challenges with severity of resiratory responses. J Allergy Clin Immunol. 1999;104:559-64. (Pubitemid 29451644)
53. Arm JP, O'Hickey S, Spur BW, et al. Airway responsiveness to histamine and leukotriene E4 in subjects with aspirin-induced asthma. Am Rev Respir Dis. 1989;140:148-53. (Pubitemid 19177096)
54. Ding XZ, Talamonti MS, Bell Jr RH, et al. A novel anti-pancreatic cancer agent, LY293111. Anti Canc Drugs. 2005;16:467-73. (Pubitemid 40685730)
55. Dahlen B, Nizankowska E, Szczeklik A. Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics. Am J Respir Critc Care Med. 1998;157:1187-94.
56. Kieff DA, Busaba NY. Efficacy of montelukast in the treatment of nasal polyposis. Ann Otol Rhinol Laryngol. 2005;114:941-5. (Pubitemid 43030937)
57. Schaper C, Noga O, Koch B, et al. Anti-inflammatory properties of montelukast, a leukotriene receptor antagonist in patients with asthma and nasal polyposis. J Investig Allergol Clin Immunol. 2011;21:51-58. Monteluekast was shown to mediate slight improvements in chronic sinusitis symptoms and reduction in nasal polyps.
58. Wilson AM, White PS, Gardiner Q, et al. Effects of leukotriene receptor antagonist therapy in patients with chronic rhinosinusitis in a real life rhinology clinic setting. Rhinology. 2001;39:142-6. (Pubitemid 33026182)
59. Parnes SM, Churna AV. Acute effects of antileukotrienes on sinonasal polyposis and sinusitis. ENT Journal. 2000;79:18-21.
60. Parnes SM. The role of leukotriene inhibitors in patients with paranasal sinus disease. Curr Opin Otolaryngol Head Neck Surg. 2003;11:184-91. (Pubitemid 36724365)
61. Di Rienzo L, Artuso A, Cerqua N. Antileukotrienes in the prevention of postoperative recurrence of nasal polyposis in ASA syndrome. Acta Otorhinolaryngol Ital. 2000;20:336-42.
62. Grundmann T, Topfner M. Treatment of ASS-Associated Polyposis (ASSAP) with a cysteinyl leukotriene receptor antagonist -a prospective drug study on its antiinflammatory effects. Laryngorhinootologie. 2001;80:576-82. (Pubitemid 33027242)
63. Hsieh FH, Lam BK, Penrose JF, et al. T helper cell type 2 cytokines coordinately regulate immunoglobulin E-dependent cysteinyl leukotriene production by human cord blood-derived mast cells: profound induction of leukotriene C4 synthase expression by interleukin 4. J Exp Med. 2001;193:123-33. (Pubitemid 32060703)
64. Mellor EA, Maekawa A, Austen KF, et al. Cysteinyl leukotriene receptor 1 is also a pyrimidinergic receptor and is expressed by human mast cells. Proc Natl Acad Sci USA. 2001;98:7964-9. (Pubitemid 32642670)
65. Lin DA, Boyce JA. IL-4 regulates MEK expression required for lysophosphatidic acid-mediated chemokine generation by human mast cells. J Immunol. 2005;175:5430-8. (Pubitemid 41456429)
66. Gevaert P, Lang-Loidolt D, Lackner A, et al. Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps. J Allergy Clin Immunol. 2006;118:1133-41. (Pubitemid 44666979)
67. Kim S, Marigowda G, Oren E, et al. Mepolizumab as a steroidsparing treatment option in patients with Churg-Strauss syndrome. J Allergy Clin Immunol. 2010;125:1336-1343. Anti-IL-5 treatment reduces eosinophil number and therefore leukotriene levels in sinus tissue. An additional benefit would be the reduction of steroid levels required in the treatment of chronic sinusitis and associated nasal polyposis.
68. Bain BJ. Relationship between idiopathic hypereosinophilic syndrome, eosinophilic leukemia, and systemic mastocytosis. Am J Hematol. 2004;77:82-5. (Pubitemid 39108803)
69. Koury MJ, Newman JH, Murray JJ. Reversal of hypereosinophilic syndrome and lymphomatoid papulosis with mepolizumab and imatinib. Am J Med. 2003;115:587-9. (Pubitemid 37352812)
70. Amrol D, Murray JJ. Alternative medical treatment strategies for chronic hyperplastic eosinophilic sinusitis. Curr Opin Otolaryngol Head Neck Surg. 2005;13:55-9. (Pubitemid 40194271)
71. Wallwork B, Coman W, Mackay-Sim A, et al. Effect of clarithromycin n nuclear factor-kappa B and transforming growth factorbeta in chronic rhinosinusitis. Laryngoscope. 2004;114:286-90. (Pubitemid 38182624)
72. Katsuta S, Osafune H, Takita R, et al. Therapeutic effect of roxithromycin on chronic sinusitis with nasal -polyps clinical, computed tomography, and electron microscopy analysis. Nihon Jibiinkoka Gakkai Kaiho. 2002;105:1189-97. (Pubitemid 36083313)
73. Bradley JD, Dmitrienko AA, Kivitz AJ, et al. A randomized, double-blinded, placebo-controlled clinical trial of LY333013, a selective inhibitor of group II secretory phospholipase A2, in the treatment of rheumatoid arthritis. J Rheumatol. 2005;32:417-23. (Pubitemid 40381410)
74. Miyake A, Yamamoto H, Takebayashi Y, et al. The novel natural product YM-26567-1 [(+)-trans-4-(3-dodecanoyl-2,4,6-trihydroxyphenyl)-7-hydroxy-2-(4- hydroxyphenyl)chroman]: a competitive inhibitor of group II phospholipase A2. J Pharmacol Exp Ther. 1992;263:1302-7. (Pubitemid 23157212)